ArticleCHEST critical care2025

Anti-CD14 treatment in patients with severe COVID-19: Clinical and biological effects in a Phase 2 randomized open-label adaptive platform clinical trial.

F Linzee Mabrey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.